Endostatin effective with head and neck cancers.
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000098:blood supply* / Q000188:drug therapy; D043169:Endostatins / Q000627:therapeutic use*; D006258:Head and Neck Neoplasms / Q000098:blood supply* / Q000188:drug therapy; D006801:Humans; D009389:Neovascularization, Pathologic / Q000188:drug therapy*
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D043169:Endostatins